BeiGene Company Insiders
BGNE Stock | USD 189.77 4.79 2.46% |
BeiGene's insiders are aggressively selling. The analysis of the overall insider sentiment regarding BeiGene suggests that all insiders are panicking. BeiGene employs about 10.6 K people. The company is managed by 16 executives with a total tenure of roughly 28 years, averaging almost 1.0 years of service per executive, having 662.5 employees per reported executive.
Xiaodong Wang Chairman CoChairman CoFounder |
John Oyler Chairman Chairman of the Board, CEO, Founder |
BeiGene's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-10-08 | John Oyler | Disposed 6175 @ 232.22 | View | ||
2024-09-30 | Chan Henry Lee | Disposed 1202 @ 237.1 | View | ||
2024-09-27 | Lai Wang | Disposed 5000 @ 220.35 | View | ||
2024-09-19 | Xiaobin Wu | Disposed 4500 @ 200.14 | View | ||
2024-09-17 | Xiaobin Wu | Disposed 500 @ 200 | View | ||
2024-09-03 | Xiaobin Wu | Disposed 5556 @ 189.65 | View | ||
2024-07-30 | Chan Henry Lee | Disposed 834 @ 160.57 | View | ||
2024-07-01 | Julia Aijun Wang | Disposed 472 @ 143.9 | View | ||
2024-06-24 | Julia Aijun Wang | Disposed 899 @ 155.66 | View | ||
2024-04-10 | John Oyler | Disposed 26716 @ 148.89 | View | ||
2024-03-12 | John Oyler | Disposed 37668 @ 164.02 | View | ||
2024-02-29 | Julia Aijun Wang | Disposed 397 @ 167.08 | View |
Monitoring BeiGene's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
BeiGene |
BeiGene's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with BeiGene's future performance. Based on our forecasts, it is anticipated that BeiGene will maintain a workforce of about 10600 employees by December 2024.BeiGene Management Team Effectiveness
The company has return on total asset (ROA) of (0.0958) % which means that it has lost $0.0958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2322) %, meaning that it created substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.32. At present, BeiGene's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 37.5 M, whereas Other Assets are forecasted to decline to 1.90.As of November 22, 2024, Common Stock Shares Outstanding is expected to decline to about 72.1 M. The current year's Net Loss is expected to grow to about (1.7 B)
BeiGene Workforce Comparison
BeiGene is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 24,721. BeiGene totals roughly 10,600 in number of employees claiming about 43% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.14) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.14. BeiGene Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BeiGene insiders, such as employees or executives, is commonly permitted as long as it does not rely on BeiGene's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, BeiGene insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 0.3077 | 4 | 13 | 364,923 | 319,658 |
2024-06-01 | 0.8158 | 31 | 38 | 4,354,727 | 64,442 |
2024-03-01 | 0.0556 | 1 | 18 | 27,794 | 147,094 |
2023-06-01 | 1.0357 | 29 | 28 | 4,937,452 | 4,361,788 |
2023-03-01 | 0.0435 | 1 | 23 | 67,635 | 1,030,922 |
2022-09-01 | 0.0526 | 2 | 38 | 15,600 | 98,486 |
2022-06-01 | 1.4375 | 23 | 16 | 9,156,654 | 1,048,091 |
2021-12-01 | 0.1039 | 8 | 77 | 78,557 | 141,237 |
2021-09-01 | 0.0433 | 9 | 208 | 207,903 | 1,706,030 |
2021-06-01 | 0.5806 | 36 | 62 | 2,773,385 | 3,301,137 |
2021-03-01 | 0.1667 | 5 | 30 | 18,500 | 460,154 |
2020-12-01 | 0.2069 | 12 | 58 | 3,559,739 | 8,714,572 |
2020-09-01 | 0.076 | 19 | 250 | 44,610,223 | 1,047,613 |
2020-06-01 | 0.2969 | 19 | 64 | 4,292,255 | 246,514 |
2020-03-01 | 0.2727 | 3 | 11 | 24,970 | 47,000 |
2019-12-01 | 0.1525 | 9 | 59 | 596,650 | 591,773 |
2019-09-01 | 0.3636 | 8 | 22 | 287,420 | 71,625 |
2019-06-01 | 1.1304 | 26 | 23 | 6,423,288 | 845,763 |
2019-03-01 | 0.0625 | 2 | 32 | 35,910 | 69,077 |
2018-12-01 | 0.0864 | 7 | 81 | 102,000 | 985,746 |
2018-09-01 | 0.1818 | 2 | 11 | 5,814,100 | 16,679 |
2018-06-01 | 13.0 | 26 | 2 | 7,104,073 | 5,000,000 |
2018-03-01 | 0.1064 | 5 | 47 | 2,025,198 | 944,865 |
2017-12-01 | 0.0714 | 3 | 42 | 9,602 | 491,501 |
2017-09-01 | 0.375 | 6 | 16 | 2,786,056 | 454,077 |
2017-06-01 | 0.8 | 12 | 15 | 6,596,420 | 220,981 |
2016-12-01 | 6.0 | 6 | 1 | 7,203,925 | 93,750 |
2016-09-01 | 0.5833 | 7 | 12 | 5,510,000 | 442,310 |
2016-03-01 | 0.8846 | 23 | 26 | 213,902,954 | 135,561,007 |
BeiGene Notable Stakeholders
A BeiGene stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BeiGene often face trade-offs trying to please all of them. BeiGene's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BeiGene's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Xiaodong Wang | CoChairman CoFounder | Profile | |
John Oyler | Chairman of the Board, CEO, Founder | Profile | |
Xiaobin Wu | President COO | Profile | |
Aaron Rosenberg | CFO Officer | Profile | |
Chan Lee | General VP | Profile | |
Titus Ball | VP Officer | Profile | |
Mi Zhou | Director Relations | Profile | |
Liza Heapes | Head Relations | Profile | |
Wang Lai | Global RD | Profile | |
Kevin Mannix | VP Relations | Profile | |
Julia Wang | Executive Officer | Profile | |
Jason Radford | Senior Development | Profile | |
Yang Ji | Chief Officer | Profile | |
Daniel Maller | VP Accounting | Profile | |
Diana Francis | VP Compliance | Profile | |
Yan Qi | Senior China | Profile |
About BeiGene Management Performance
The success or failure of an entity such as BeiGene often depends on how effective the management is. BeiGene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BeiGene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BeiGene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.15) | (0.16) | |
Return On Capital Employed | (0.30) | (0.32) | |
Return On Assets | (0.15) | (0.16) | |
Return On Equity | (0.25) | (0.26) |
Please note, the presentation of BeiGene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BeiGene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BeiGene's management manipulating its earnings.
BeiGene Workforce Analysis
Traditionally, organizations such as BeiGene use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BeiGene within its industry.BeiGene Manpower Efficiency
Return on BeiGene Manpower
Revenue Per Employee | 232K | |
Revenue Per Executive | 153.7M | |
Net Loss Per Employee | 83.2K | |
Net Loss Per Executive | 55.1M | |
Working Capital Per Employee | 225.8K | |
Working Capital Per Executive | 149.6M |
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Stocks Directory Find actively traded stocks across global markets | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |